For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen to evaluate Pfizer asset to normalize circadian rhythm-associated Alzheimer’s, Parkinson’s symptoms

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease.

Monday’s deal is

Read the full 314 word article

How to gain access

Continue reading with a
two-week free trial.